Genomic Center - Projects



H2020-MSCA-RISE-2018- nr 824036- Excellence in research and development of non-coding RNA DIAGnostics in Oncology - RNADIAGON

Period 2018-2023

H2020-MSCA-RISE-2019- Grant Agreement no.: 872391 – “Development of Cancer

RNA Therapeutics CONCRETE

 Period 2019-2024

D-CARE 656/2020 - Developing, piloting and validating smart care models in Danube region for supporting social innovation, improving competences and entrepreneurship

 Period 2020-2022



PN-III-P4-ID-PCE-2020-1625 Testing small molecule targeting mitogen activated protein kinases: Successes, challenges and opportunities in triple negative breast cancer systems

Period 2021-2024


PN-III-P4-ID-PCE2020-1756 Low-moderate drinking water arsenic contamination, cigarette smoke and adverse pregnancy outcomes in timis county

Period 2021-2024


PN-III-P4-ID-PCE2020-2486 Modulation of the trained immunity by vaccination amplifiers MOTIVA

Period 2021-2024


PN-III-P1-1.2-PCCDI-2017-0737 ctr. 35 PCCDI Genomic population mapping of radioactive and heavy metals in order to increase national security - ARTEMIS

Period 2017 – 2021


POC-P_37_796 /2016 ctr 35/01.09.2016 Clinical and economic impact of personalized targeted therapies with anti - microARN in reconverting resistance of malignant lung tumors - CANTEMIR

Period: 2016-2021


POCU/380/6/13 - cod 125171 Academy of Researchers Entrepreneurs in Medicine

Period: 2019-2021

POC/398/1/1 - ID 125371 – Increasing the research capacity of UMF Iuliu Hațieganu Cluj Napoca, by developing a CLOUD type infrastructure connected to global information resources - CYRUS,

Period 2020-2021

PN-III-P2-2.1-PED-2019-2536 - ctr. 557PED/2020 Development of an intelligent combined imagistic - cytologic – molecular system to guide the diagnosis, risk stratification and the management of thyroid cancer (acronym - TIRCITOGEN)

Period 2020-2022



International Projects 

H2020-WIDESPREAD-2016-2017 ID  763560 

Teaming Phase1 Romanian Centre of Excellence for Systems Immunology - ROCSI

Period: 2017-2018

PN-III-P3-3.1-PM-RO-CN-2018-0083 (Bilateral Cooperation Romania-China)

Experimental immunotherapy for haematological malignancie

Period 2018-2019

PN-III-P1-1.1-BT-2016-0021 SEE-027 - 1 / 25.06.2015  

Innovative Nanoparticles-based  Chemotherapy  for Acute Myeloid Leukemia

Period: 2015-2016

PN-II-CT-RO-ZA-2014 – 1 ctr 7 BM/2016 (Bilateral Funding Romania- South Africa)

Use of new nanogold materials as delivery systems for modulation of MCL-1/p53 siRNA in ALL - NanoLAL

Period: 2016 – 2017


American International School of Bucharest (TERRY FOX) ctr.1110/23.07.2015

MicroRNAs biomarkers of response to chemotherapy and overall survival in colon cancer 

Period: 2015-2016


57 BM/2016 Bilateral Funding (Beijing)

Non-invasive biomarkers for graft versus host disease following bone marrow hematopoietic stem cell transplantation

Period 2016-2017 



24SOL / 20.07.2020 Emergency development of molecular instruments for emergency and re-emergence assessment COVID-19

Period 2020


PNCDI III 2015-2020 - Ctr. nr. 29PFE/18.10.2018

Increasing the performance of scientific research and technology transfer in translational medicine through the formation of a new generation of young researchers - ECHITAS

Period 2018-2020



Addressing the complex exposome profile in hormone-dependent cancers of the breast and prostate and its influence on tumoral genome – ACHILLE

Period: 2017-2019 



Sustenance and valorification of research of excellence in the domain of personalized medicine by internationalization and increasement of research activities visibility

Period may 2019 – december 2019



Targeting breast cancer resistance mechanism with combinatorial drug therapy using small molecules and siRNA, in post genomic era- DRUG_STORE

Period: 2018-2020



Mobility Projects for Young Researchers from the Diaspora. Professor Guest: Dr. Gabriel Ghiaur

Period 2018


PN-III-P1-1.1-MC-2018-0195 MC

Mobility Projects for Researchers Ciprian Tomuleasa

Period 2018



Correlation of the educational offer in molecular medicine and translational onco-hematology with the demand on the labor market at European level

Period 2018



Modern training for healthcare professionals affiliated to the departments of hematology, oncology and bone marrow transplantation

Period 2017



FSS Project to implement activities to identify and promote innovative student-initiated ideas, business ideas, entrepreneurship and student start-ups 2017

Period 2017


Massively parallel high-throughput DNA sequencing for the identification of microRNAs differentially expressed between the metastatic site and the tissue of origin in cancers of unknown primary site

Period: 2015-2017
PN-II-RU-TE-2014-4-1464 ctr.307/2015

TGF β signaling pathway tapering: an alternative to TGFtarget breast cancer therapy

Period: 2015-2017

 PN-III-P1-1.1-MCD-2016-0049 MCD 

Mobility projects for researchers with experience from diaspora (Prof.Dr. George Adrian Calin)

Period 2016

PN-II-PT-PCCA-2013-4-2289 Ctr. 137/2014

Developing a method for real-time detection and isolation of circulating tumor cells from the bloodstream of cancer patients by means of image processing and pattern recognition - CTC VideoScop

Period: 2014- 2017

F-SEE Romania – European Economic Space (EES) cod F-SEE-003/07.2013

Nanotechnology approach in Acute Myeloid Leukemia management” –   NanoLAM.  1 / 16.01.2014, 

Period 2014-2016

PN-II-PT-PCCA-2013-4-2166 ctr. 128/2014

New strategies for improving cancer patient’s quality of life and survival: molecular and clinical studies of cancer genome using depleted deuterium water model- GenCanD”

Period: 2014 - 2017

PN-II-PT-PCCA-2013-4-0030 ctr.196/2014 

Modulation of pro/anticarcinogenic effect of toxic chemical agents in breast cancer multitargeted therapy - CANCERTER-p53

Period:  2014- 2017  
PN-II-PT-PCCA-2013-4-1959 ctr.193/2014 Non-Invasive Intelligent Systems for Colorectal Cancer Diagnosis and Prognosis Based on Circulating miRNA Integrated in the Clinical Workflow – INTELCOR 

Period: 2014-2017
ESR-14-10102/17.10.2014 ASTRA ZENECA Ctr.ESR-14-10102/17.10.2014

BRCA1 and BRCA2 mutation analysis in Romanian population: a study of genotype-phenotype correlation at diagnosis with prospective disease outcome and survival”. 

Period: 2014-2016  

PN-II-PT-PCCA-2011-3.1-1221 Ctr. 125/2012 

Inteligent Systems of prediction of recurrence and progression in superficial bladder cancer based on artificial intelligence and microarray data: tumor mRNA and plasmatic microRNA - IntelUro 

Period:  2012 -  2016

PN-II-PT-PCCA-2011-3.2-1328 Ctr. 96/2012 

Analysis of microRNA biomarkers as predictive values for cervical cancer treatment, in relationship with environmental exposure to arsenic, phthalates and ETS - CERVICALL-ARSEN-ARRAY 

Period: 2012 -  2016

POSCEE 2010 nr. 709/12683 ctr. 228/06.08.2010

Clinical and Economical Impact of the transcriptomic and proteomic molecular profile identification in the neoadjuvant therapy of triple negative breast cancer”-BREASTIMPACT

Period: 2010- 2014


Fellowship of the young researcher

Osan Ciprian-Ioan

Period 2017-2018

Program L’Oréal - UNESCO FOR WOMEN IN SCIENCE, Life Sciences Section- 4th edition (2012 - 2013), with a project entitled “Combining the chemotherapeutic effect of doxorubicin with RNA interference targeted therapy in the treatment of triple negative breast cancer” Cornelia Braicu


Identifying a methylation profile of cancer-associated genes in squamous cell carcinoma 

Period: 2016-2018


MicroRNA analysis in breast cancer late apoptotic mechanisms Pileczki Valentina - 

Period 2014-2015


Cell and molecular mechanisms of primary myelofibrosis Tomuleasa Ciprian

Period 2014-2015


Circulating miRNAs as biomarkers for metastatic colorectal cancer - Petric Roxana

Period 2014-2015


Target therapy in triple-negative breast cancer: evaluation of DNMT3b inhibition with nanaomycin A (students)


A syntetic lethalaty approach in the acute myeloid leukaemia chemotherapy : PARP inhibitors plus anthreacycline plus decitabine vs anthreacycline plus decitabine – in vitro efficacy testing(students)

Period: 2016-2018

The efficacy of pirfenidone in the treatment of primary myelofibrosis (students)

Period: 2016-2018